Galaxy MedicareNSE:GML -3.51%19 EBITDA Margin % is 11.04% as of Mar. 2026, which is 20% below its 10-year median of 13.84. GuruFocus rates NSE:GML with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Galaxy Medicare ranks better than 62.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Galaxy Medicare's EBITDA for the
six
months ended in Mar. 2026 was ₹23.5 Mil. Galaxy Medicare's Revenue for the
six
months ended in Mar. 2026 was ₹212.7 Mil. Therefore, Galaxy Medicare's EBITDA margin for the quarter that ended in Mar. 2026 was 11.04%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Galaxy Medicare EBITDA Margin % Related Terms
Galaxy Medicare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Galaxy Medicare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GML vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Galaxy Medicare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galaxy Medicare EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Galaxy Medicare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Galaxy Medicare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galaxy Medicare (NSE:GML) has a EBITDA Margin % of 11.04% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Galaxy Medicare and its competitors. This is 20% below median its historical median of 13.84. Over the past decade, Galaxy Medicare's EBITDA Margin % has ranged from 6.25 to 16.99. According to the industry distribution chart, Galaxy Medicare ranks #303 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 37.1%.
Is Galaxy Medicare's EBITDA Margin % too high?
Galaxy Medicare's current EBITDA Margin % of 11.04% is 20% below median its 10-year median of 13.84. Over the past 10 years, this metric has ranged from a low of 6.25 to a high of 16.99. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Galaxy Medicare's value of 11.04% is 47.7% above this industry median. Based on the distribution chart, Galaxy Medicare ranks #303 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Galaxy Medicare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Galaxy Medicare's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Galaxy Medicare ranks #303 out of 816 companies for EBITDA Margin %. This puts Galaxy Medicare in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Galaxy Medicare's value of 11.04% is 47.7% above this benchmark. Historically, Galaxy Medicare's own EBITDA Margin % has ranged from 6.25 to 16.99 over the past decade. While the company's 10-year median is 13.84 vs. the industry median of 7.48, Galaxy Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galaxy Medicare's current EBITDA Margin % of 11.04% is 47.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Galaxy Medicare and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galaxy Medicare's current EBITDA Margin % is 11.04%, which is 20% below median its own 10-year median of 13.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galaxy Medicare stock overvalued right now?
Galaxy Medicare (NSE:GML) has a current EBITDA Margin % of 11.04%. The current EBITDA Margin % is 11.04%, which is 20% below median its 10-year median of 13.84 and 47.7% above the Medical Devices & Instruments industry median of 7.48. Galaxy Medicare's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Galaxy Medicare (NSE:GML), the current EBITDA Margin % is 11.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galaxy Medicare Ltd is engaged into the manufacturing, trading and exporting of Medical Devices, Plasters of Paris Bandages (POP Bandage) and Other surgical dressings in India. Its business encompass: Manufacturing and Branding of its own products under its flagship brands i.e. POP BAND, POP CAST, G CAST, GYPSOSOFT, GYPSOPLAST, CARETAPE, GYPSOCREPE, CARECREPE, CAREPORE GYPSONET, GYPSOCHLOR, FIXCAN ETC.
19GF Score
Get the complete analysis for NSE:GML
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GML has been successfully added to your 